Tan AC, et al. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299–312.

Article  PubMed  Google Scholar 

Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.

Article  PubMed  PubMed Central  Google Scholar 

Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porter DL, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chuntova P, et al. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021;23(3):356–75.

Article  CAS  PubMed  Google Scholar 

Khasraw M, et al. PD-1 inhibitors: do they have a future in the treatment of glioblastoma? Clin Cancer Res. 2020;26(20):5287–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miranda WY, Daniela FQ. Immunotherapy for glioblastoma: current progress and challenges. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.78268.

Article  PubMed  PubMed Central  Google Scholar 

Lim M, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15:422–42.

Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29(1):58–69.

CAS  PubMed  PubMed Central  Google Scholar 

Andersson PB, Perry VH, Gordon S. The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neuroscience. 1992;48(1):169–86.

Article  CAS  PubMed  Google Scholar 

Locatelli G, et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci. 2012;15(4):543–50.

Article  CAS  PubMed  Google Scholar 

Mrdjen D, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48(2):380-95.e6.

Article  CAS  PubMed  Google Scholar 

Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.

Article  PubMed  Google Scholar 

Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Q, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42-56.e6.

Article  PubMed  PubMed Central  Google Scholar 

Doucette T, et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the Cancer Genome Atlas. Cancer Immunol Res. 2013;1(2):112–22.

Article  CAS  PubMed  Google Scholar 

Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez-Lage M, et al. Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol Commun. 2019;7(1):203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visish MS, et al. Tumor vaccines for malignant gliomas. Neurotherapeutics. 2017;14:345–57.

Article  Google Scholar 

Hodges TR, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017;19:1047–57.

Weller M, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer. 2014;134:2437–47.

Weller M, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–85.

Sanson M, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150–4.

Schumacher T, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512:324–7.

Article  CAS  PubMed  Google Scholar 

Bunse L, et al. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Investig. 2015;125(2):593–606.

PubMed  PubMed Central  Google Scholar 

Bunse L, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018;24(8):1192–203.

Article  CAS  PubMed  Google Scholar 

Platten M, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021;592:463–8.

Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–9.

Garg H, et al. Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016;16:49.

Kajiwara Y, et al. Expression of survivin in astrocytic tumors. Cancer. 2003;97:1077–83.

Fenstermaker RA, et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016;65(11):1339–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciesielski MJ, et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010;59:1211–21.

Sanchez VE, et al. GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models. Sci Rep. 2020;10(1):11003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalani MYS, et al. Wnt-mediated self-renewal of neural stem/progenitor cells. Proc Nat Acad Sci. 2008;105:16970–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2001;2:120–9.

Clark AJ, et al. Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg. 2007;107:586–92.

Rushing EJ, et al. High-grade astrocytomas show increased Nestin and Wilms’s Tumor Gene (WT1) protein expression. Int J Surg Pathol. 2010;18:255–9.

Ruggiero E, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022;14:eabg8027.

Hashimoto N, et al. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunol Immunother. 2015;64:707–16.

Kawanishi Y, et al. IMT-03 clinical trial for newly diagnosed malignant glioma with WT1-W10 vaccination. Neuro Oncol Adv. 2019;1(Suppl_2):ii17.

Article  Google Scholar 

Steinman RM, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191:411–6.

Sampson JH, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8:2773–9.

Sakai K, et al. Dendritic cell-based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma. J Neurosurg. 2015;123:989–97.

Huang B, et al. Current immunotherapies for glioblastoma multiforme. Front Immunol. 2021;11:603911.

Mitchell DA, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9.

Weathers SP, et al. Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses: results from a phase I/II trial. Clin Cancer Res. 2020;26(14):3565–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu JS, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973–9.

Article  CAS  PubMed  Google Scholar 

Ye L, et al. Identification of tumor antigens and immune landscape in glioblastoma for mRNA vaccine development. Front Genet. 2021;12:701065.

Wu C, et al. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. J Big Data. 2022;9:92.

Lin H, et al. Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development. Front Immunol. 2022;13:249.

Google Scholar 

Chen R, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17:362–75.

Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.

Fidoamore A, et al. Glioblastoma stem cells microenvironment: the paracrine roles of the niche in drug and radioresistance. Stem Cells Int. 2016;2016:1–17.

Do ASS, et al. CD133 mRNA-loaded dendritic cell vaccination abrogates glioma stem cell propagation in humanized glioblastoma mouse model. Mol Ther Oncolytics. 2020;18:295–303.

Nair SK, et al. Immunological targeting of cytomegalovirus for glioblastoma therapy. OncoImmunology. 2014;3: e29289.

Rampling R, et al. A Cancer Research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res. 2016;22:4776–85.

Phuphanich S, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62:125–35.

Wen PY, et al. A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 2019;25:5799–807.

Craig EA, et al. Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell. 1994;78:365–72.

Graner MW, Bigner DD. Chaperone proteins and brain tumors: Potential targets and possible therapeutics. Neuro Oncol. 2005;7:260–8.

Crane CA, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013;19:205–14.

Bloch O, et al. Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014;16:274–9.

Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.

Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125:3393–400.

Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20:75–6.

Dai S, et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290:72–9.

Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84.

Nduom EK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195–205.

Article  CAS  PubMed  Google Scholar 

Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.

Article  PubMed  Google Scholar